Bullish & Foolish
Full IBIO fundamentals All 466 on the Survival Watch

IBIOiBio, Inc.

Is iBio struggling financially?

Yes, by its own account. iBio told the SEC on 12 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$71.0M
Source filing
10-Q 12 May 2026
Balance sheet
31 Mar 2026

Cash runway

31+ mo

Runs out some time after Oct 2028, raising nothing.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$47.6M

÷

Cash burned over the last 12 months

$15.3M

What iBio told the SEC

…negative cash flow from operations, and the dependence by the Company on its ability to obtain additional financing to fund its operations in the past raised substantial doubt about the Company's ability to continue as a going concern. In August 2025, the Company closed on an underwritten public offering raising gross proceeds of approximately $ 50 million and in January 2026, the Company raised gross proceeds of…

iBio, Inc., Form 10-Q, filed 12 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 881.3% share-count increase The company issued stock. Each share now owns 89.8% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 43% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt